Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

48.88 +0.42 (+0.87%)
Streaming Delayed Price Updated: 12:00 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 81,938
Open 49.36
Bid (Size) 48.69 (1)
Ask (Size) 49.10 (2)
Prev. Close 48.46
Today's Range 48.72 - 49.97
52wk Range 26.70 - 91.83
Shares Outstanding 44,712,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-38.5%
-38.5%
1 Month
-8.8%
-8.8%
3 Month
+31.0%
+31.0%
6 Month
-42.0%
-42.0%
1 Year
-5.7%
-5.7%

More News

Read More
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Earnings Scheduled For August 4, 2025
Via Benzinga
What to Expect from Praxis Precision Medicine's Earnings
Via Benzinga
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Via Benzinga
Praxis (PRAX) Q2 Loss Widens 90%
Via The Motley Fool
Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine
Via Chartmill
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Via Investor's Business Daily
Topics Intellectual Property
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
Via Benzinga
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts
Via Benzinga
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings)
Via Benzinga

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?
Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.
What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?
Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?
The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market
What is the current price of Praxis Precision Medicines, Inc. - Common Stock?
The current price of Praxis Precision Medicines, Inc. - Common Stock is 48.88
When was Praxis Precision Medicines, Inc. - Common Stock last traded?
The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 08/13/25 12:00 PM ET
What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?
The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 2.19B
How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?
Praxis Precision Medicines, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.